Shopping Cart
- Remove All
- Your shopping cart is currently empty
MDX-1342, a fully human monoclonal antibody (HuMAb), targets the CD19 membrane receptor with high specificity and affinity. It exhibits antibody-dependent cellular cytotoxicity (ADCC) and is utilized in researching B-lymphocyte malignancies and autoimmune diseases [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | MDX-1342, a fully human monoclonal antibody (HuMAb), targets the CD19 membrane receptor with high specificity and affinity. It exhibits antibody-dependent cellular cytotoxicity (ADCC) and is utilized in researching B-lymphocyte malignancies and autoimmune diseases [1]. |
In vitro | MDX-1342 (0-100 μg/mL; 30 min) binds to Ramos, Raji, and ARH-77 cells, demonstrating EC50 values of 0. |
In vivo | MDX-1342 administered intravenously at doses of 0.03, 0.3, 3, and 30 mg/kg in a 200 μL volume enhances survival in a dose-dependent manner in a mouse B-cell lymphoma model [1]. At single doses of 0.1 or 1 mg/kg, MDX-1342 exhibits low nanomolar affinity for CD19 in cynomolgus monkeys, increased binding to cynomolgus monkey FcγRIIIa, and demonstrates effective B-cell depletion in vivo [1]. |
Cas No. | 1646327-65-2 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.